$84.5m market cap
$1.25 last close
Sunesis Pharmaceuticals is a pharmaceutical company focused on oncology. The company has developed vecabrutinib, a BTK inhibitor for CLL for Imbruvica refractory patients currently in Phase I/II.
Investment summary
Sunesis is currently in the dose-escalation portion of the Phase Ib/II study of its BTK inhibitor vecabrutinib, and the first signs of clinical efficacy are expected in the upcoming doses. The drug is being tested in a range of B-cell malignancies where BTK inhibitors have historically shown some activity. The company will provide its next clinical update at the European Hematology Association (EHA) Congress in June 2019. In this note we review the clinical data to date and provide our clinical outlook.
Y/E Dec |
Revenue (US$m) |
EBITDA (US$m) |
PBT (US$m) |
EPS (c) |
P/E (x) |
P/CF (x) |
|---|---|---|---|---|---|---|
| 2017A | 0.7 | (34.4) | (35.5) | (144.63) | N/A | N/A |
| 2018A | 0.2 | (25.7) | (26.6) | (74.80) | N/A | N/A |
| 2019E | 0.0 | (28.1) | (28.7) | (41.68) | N/A | N/A |
| 2020E | 0.0 | (29.3) | (33.3) | (46.23) | N/A | N/A |
| Last updated on 22/03/2019 | ||||||
Industry outlook
Sunesis is an oncology company with an early stage asset with a validated target targeting patients that are in B-cell malignancies.
Last updated on 22/03/2019
Sector |
|---|
| Healthcare |
Share price graph
Balance sheet |
|
|---|---|
| Forecast net debt (US$m) | 0 |
| Forecast gearing ratio (%) | 117 |
Price performance
% |
1m |
3m |
12m |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|||||||||||||||
| *% relative to local index | |||||||||||||||
Key management |
|
|---|---|
| William Quinn | Chief Financial Officer and Senior Vice Presi |
